Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply, High Purity, Commercial Production Chemical Name: Linagliptin CAS: 668270-12-0Item | Specifications |
Appearance | White or Off-White Crystalline Powder |
NMR | Consistent With Structure |
Purity / Analysis Method | ≥99.0% (HPLC) |
Loss on Drying | ≤0.50% |
Residue on Ignition | ≤0.10% |
Heavy Metals | ≤10ppm |
Related Substances | |
Single Impurity | ≤0.50% |
Total Impurities | ≤1.0% |
Isomer | ≤0.15% |
Residual Solvents | |
Methanol | ≤3000ppm |
Isopropanol | ≤5000ppm |
DMF | ≤800ppm |
Dichloromethane | ≤600ppm |
Test Standard | Enterprise Standard |
Usage | API |
Description:
Specifications:
Package & Storage:
Chemical Name | Linagliptin |
Synonyms | BI-1356; 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione |
CAS Number | 668270-12-0 |
CAT Number | RF-API105 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C25H28N8O2 |
Molecular Weight | 472.54 |
Melting Point | 197.0 to 200.0℃ |
Solubility | Soluble in DMSO |
Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Linagliptin (CAS: 668270-12-0) is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Linagliptin, sold under the brand name Tradjenta among others. It is used together with exercise and diet.